US court finds Astra Seroquel XR patent infringed
March 29 (Reuters) - A U.S. court on Thursday ruled that the formulation patent for AstraZeneca's big-selling anti-psychotic drug Seroquel XR was valid and had been infringed by Mylan Inc and other companies seeking to sell cheap generic versions of the medicine.
The judgment by the U.S. District Court for the District of New Jersey is limited to the U.S. market only, AstraZeneca said.
Seroquel XR, a longer acting version of Seroquel which also treats depression and bipolar disorder, has annual U.S. sales of about $750 million.
- Housing, jobs data weaken, but overall economic picture still upbeat
- Putin critic Khodorkovsky in Germany after pardon |
- Target cyber breach hits 40 million payment cards at holiday peak |
- Pizza outlet attacked as India, U.S. fail to cool diplomat row |
- New York Mayor-elect's reputation for lateness parodied on Twitter